This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mosier, D. E.
Right arrow Articles by Wilken, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mosier, D. E.
Right arrow Articles by Wilken, J.

 Previous Article  |  Next Article 

Journal of Virology, May 1999, p. 3544-3550, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variantsdagger

Donald E. Mosier,1,* Gastón R. Picchio,1 Richard J. Gulizia,1 Rebecca Sabbe,1 Pascal Poignard,1 Laurent Picard,2 Robin E. Offord,3,4 Darren A. Thompson,4 and Jill Wilken4

Department of Immunology-IMM7, The Scripps Research Institute, La Jolla, California 920371; INSERM U.332, Institut Cochin de Génétique Moléculaire, 75014 Paris, France2; Department de Biochimie Médicale, Centre Médical Universitaire, 1211 Geneva 4, Switzerland3; and Gryphon Sciences, South San Francisco, California 940804

Received 28 September 1998/Accepted 20 January 1999

The natural ligands for the CCR5 chemokine receptor, macrophage inflammatory protein 1alpha (MIP-1alpha ), MIP-1beta , and RANTES (regulated on T-cell activation, normal T-cell expressed and secreted), are known to inhibit human immunodeficiency virus (HIV) entry, and N-terminally modified RANTES analogues are more potent than native RANTES in blocking infection. However, potent CCR5 blocking agents may select for HIV-1 variants that use alternative coreceptors at less than fully inhibitory concentrations. In this study, two N-terminal chemical modifications of RANTES produced by total synthesis, aminooxypentane (AOP)-RANTES[2-68] and N-nonanoyl (NNY)-RANTES[2-68], were tested for their ability to prevent HIV-1 infection and to select for coreceptor switch variants in the human peripheral blood lymphocyte-SCID mouse model. Mice were infected with a CCR5-using HIV-1 isolate that requires only one or two amino acid substitutions to use CXCR4 as a coreceptor. Even though it achieved lower circulating concentrations than AOP-RANTES (75 to 96 pM as opposed to 460 pM under our experimental conditions), NNY-RANTES was more effective in preventing HIV-1 infection. However, in a subset of treated mice, these levels of NNY-RANTES rapidly selected viruses with mutations in the V3 loop of envelope that altered coreceptor usage. These results reinforce the case for using agents that block all significant HIV-1 coreceptors for effective therapy.

* Corresponding author. Mailing address: Department of Immunology-IMM7, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Phone: (619) 784-9121. Fax: (619) 784-9190. E-mail: dmosier{at}scripps.edu.

dagger Publication no. 11734-IMM from The Scripps Research Institute.

Journal of Virology, May 1999, p. 3544-3550, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Nakata, H., Steinberg, S. M., Koh, Y., Maeda, K., Takaoka, Y., Tamamura, H., Fujii, N., Mitsuya, H. (2008). Potent Synergistic Anti-Human Immunodeficiency Virus (HIV) Effects Using Combinations of the CCR5 Inhibitor Aplaviroc with Other Anti-HIV Drugs. Antimicrob. Agents Chemother. 52: 2111-2119 [Abstract] [Full Text]  
  • Lobritz, M. A., Marozsan, A. J., Troyer, R. M., Arts, E. J. (2007). Natural Variation in the V3 Crown of Human Immunodeficiency Virus Type 1 Affects Replicative Fitness and Entry Inhibitor Sensitivity. J. Virol. 81: 8258-8269 [Abstract] [Full Text]  
  • Kiselyeva, Y., Nedellec, R., Ramos, A., Pastore, C., Margolis, L. B., Mosier, D. E. (2007). Evolution of CXCR4-Using Human Immunodeficiency Virus Type 1 SF162 Is Associated with Two Unique Envelope Mutations. J. Virol. 81: 3657-3661 [Abstract] [Full Text]  
  • Westby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mosley, M., Stockdale, M., Dorr, P., Ciaramella, G., Perros, M. (2007). Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry. J. Virol. 81: 2359-2371 [Abstract] [Full Text]  
  • Pastore, C., Nedellec, R., Ramos, A., Pontow, S., Ratner, L., Mosier, D. E. (2006). Human Immunodeficiency Virus Type 1 Coreceptor Switching: V1/V2 Gain-of-Fitness Mutations Compensate for V3 Loss-of-Fitness Mutations. J. Virol. 80: 750-758 [Abstract] [Full Text]  
  • Ribeiro, R. M., Hazenberg, M. D., Perelson, A. S., Davenport, M. P. (2006). Naive and Memory Cell Turnover as Drivers of CCR5-to-CXCR4 Tropism Switch in Human Immunodeficiency Virus Type 1: Implications for Therapy. J. Virol. 80: 802-809 [Abstract] [Full Text]  
  • Nguyen, D. G., Wolff, K. C., Yin, H., Caldwell, J. S., Kuhen, K. L. (2006). "UnPAKing" Human Immunodeficiency Virus (HIV) Replication: Using Small Interfering RNA Screening To Identify Novel Cofactors and Elucidate the Role of Group I PAKs in HIV Infection. J. Virol. 80: 130-137 [Abstract] [Full Text]  
  • Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B., Wood, A., Perros, M. (2005). Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity. Antimicrob. Agents Chemother. 49: 4721-4732 [Abstract] [Full Text]  
  • Takashima, K., Miyake, H., Kanzaki, N., Tagawa, Y., Wang, X., Sugihara, Y., Iizawa, Y., Baba, M. (2005). Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 Antagonist. Antimicrob. Agents Chemother. 49: 3474-3482 [Abstract] [Full Text]  
  • Hartley, O., Gaertner, H., Wilken, J., Thompson, D., Fish, R., Ramos, A., Pastore, C., Dufour, B., Cerini, F., Melotti, A., Heveker, N., Picard, L., Alizon, M., Mosier, D., Kent, S., Offord, R. (2004). Medicinal chemistry applied to a synthetic protein: Development of highly potent HIV entry inhibitors. Proc. Natl. Acad. Sci. USA 101: 16460-16465 [Abstract] [Full Text]  
  • Marozsan, A. J., Fraundorf, E., Abraha, A., Baird, H., Moore, D., Troyer, R., Nankja, I., Arts, E. J. (2004). Relationships between Infectious Titer, Capsid Protein Levels, and Reverse Transcriptase Activities of Diverse Human Immunodeficiency Virus Type 1 Isolates. J. Virol. 78: 11130-11141 [Abstract] [Full Text]  
  • Lederman, M. M., Veazey, R. S., Offord, R., Mosier, D. E., Dufour, J., Mefford, M., Piatak, M. Jr., Lifson, J. D., Salkowitz, J. R., Rodriguez, B., Blauvelt, A., Hartley, O. (2004). Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5. Science 306: 485-487 [Abstract] [Full Text]  
  • Kenakin, T. (2004). Allosteric Modulators: The New Generation of Receptor Antagonist. Mol. Interv. 4: 222-229 [Abstract] [Full Text]  
  • Pastore, C., Ramos, A., Mosier, D. E. (2004). Intrinsic Obstacles to Human Immunodeficiency Virus Type 1 Coreceptor Switching. J. Virol. 78: 7565-7574 [Abstract] [Full Text]  
  • Kawamura, T., Bruce, S. E., Abraha, A., Sugaya, M., Hartley, O., Offord, R. E., Arts, E. J., Zimmerman, P. A., Blauvelt, A. (2004). PSC-RANTES Blocks R5 Human Immunodeficiency Virus Infection of Langerhans Cells Isolated from Individuals with a Variety of CCR5 Diplotypes. J. Virol. 78: 7602-7609 [Abstract] [Full Text]  
  • Moore, J. P., Doms, R. W. (2003). The entry of entry inhibitors: A fusion of science and medicine. Proc. Natl. Acad. Sci. USA 100: 10598-10602 [Abstract] [Full Text]  
  • Hartley, O., Dorgham, K., Perez-Bercoff, D., Cerini, F., Heimann, A., Gaertner, H., Offord, R. E., Pancino, G., Debre, P., Gorochov, G. (2003). Human Immunodeficiency Virus Type 1 Entry Inhibitors Selected on Living Cells from a Library of Phage Chemokines. J. Virol. 77: 6637-6644 [Abstract] [Full Text]  
  • Miyake, H., Iizawa, Y., Baba, M. (2003). Novel Reporter T-Cell Line Highly Susceptible to Both CCR5- and CXCR4-Using Human Immunodeficiency Virus Type 1 and Its Application to Drug Susceptibility Tests. J. Clin. Microbiol. 41: 2515-2521 [Abstract] [Full Text]  
  • Kilby, J. M., Eron, J. J. (2003). Novel Therapies Based on Mechanisms of HIV-1 Cell Entry. NEJM 348: 2228-2238 [Full Text]  
  • Pastore, C., Picchio, G. R., Galimi, F., Fish, R., Hartley, O., Offord, R. E., Mosier, D. E. (2003). Two Mechanisms for Human Immunodeficiency Virus Type 1 Inhibition by N-Terminal Modifications of RANTES. Antimicrob. Agents Chemother. 47: 509-517 [Abstract] [Full Text]  
  • Tremblay, C. L., Giguel, F., Kollmann, C., Guan, Y., Chou, T.-C., Baroudy, B. M., Hirsch, M. S. (2002). Anti-Human Immunodeficiency Virus Interactions of SCH-C (SCH 351125), a CCR5 Antagonist, with Other Antiretroviral Agents In Vitro. Antimicrob. Agents Chemother. 46: 1336-1339 [Abstract] [Full Text]  
  • Munch, J., Standker, L., Pohlmann, S., Baribaud, F., Papkalla, A., Rosorius, O., Stauber, R., Sass, G., Heveker, N., Adermann, K., Escher, S., Kluver, E., Doms, R. W., Forssmann, W.-G., Kirchhoff, F. (2002). Hemofiltrate CC Chemokine 1[9-74] Causes Effective Internalization of CCR5 and Is a Potent Inhibitor of R5-Tropic Human Immunodeficiency Virus Type 1 Strains in Primary T Cells and Macrophages. Antimicrob. Agents Chemother. 46: 982-990 [Abstract] [Full Text]  
  • Farber, J. M., Berger, E. A. (2002). HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!. Proc. Natl. Acad. Sci. USA 99: 1749-1751 [Full Text]  
  • Trkola, A., Kuhmann, S. E., Strizki, J. M., Maxwell, E., Ketas, T., Morgan, T., Pugach, P., Xu, S., Wojcik, L., Tagat, J., Palani, A., Shapiro, S., Clader, J. W., McCombie, S., Reyes, G. R., Baroudy, B. M., Moore, J. P. (2002). HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. USA 99: 395-400 [Abstract] [Full Text]  
  • Pontow, S., Ratner, L. (2001). Evidence for Common Structural Determinants of Human Immunodeficiency Virus Type 1 Coreceptor Activity Provided through Functional Analysis of CCR5/CXCR4 Chimeric Coreceptors. J. Virol. 75: 11503-11514 [Abstract] [Full Text]  
  • Saphire, A. C. S., Bobardt, M. D., Zhang, Z., David, G., Gallay, P. A. (2001). Syndecans Serve as Attachment Receptors for Human Immunodeficiency Virus Type 1 on Macrophages. J. Virol. 75: 9187-9200 [Abstract] [Full Text]  
  • Bahr, G. M., Darcissac, E. C. A., Casteran, N., Amiel, C., Cocude, C., Truong, M.-J., Dewulf, J., Capron, A., Mouton, Y. (2001). Selective Regulation of Human Immunodeficiency Virus-Infected CD4+ Lymphocytes by a Synthetic Immunomodulator Leads to Potent Virus Suppression In Vitro and in hu-PBL-SCID Mice. J. Virol. 75: 6941-6952 [Abstract] [Full Text]  
  • Hogan, C. M., Hammer, S. M. (2001). Host Determinants in HIV Infection and Disease: Part 2: Genetic Factors and Implications for Antiretroviral Therapeutics. ANN INTERN MED 134: 978-996 [Abstract] [Full Text]  
  • Sabbe, R., Picchio, G. R., Pastore, C., Chaloin, O., Hartley, O., Offord, R., Mosier, D. E. (2001). Donor- and Ligand-Dependent Differences in C-C Chemokine Receptor 5 Reexpression. J. Virol. 75: 661-671 [Abstract] [Full Text]  
  • Ajuebor, M. N., Hogaboam, C. M., Kunkel, S. L., Proudfoot, A. E. I., Wallace, J. L. (2001). The Chemokine RANTES Is a Crucial Mediator of the Progression from Acute to Chronic Colitis in the Rat. J. Immunol. 166: 552-558 [Abstract] [Full Text]  
  • Detheux, M., Standker, L., Vakili, J., Munch, J., Forssmann, U., Adermann, K., Pohlmann, S., Vassart, G., Kirchhoff, F., Parmentier, M., Forssmann, W.-G. (2000). Natural Proteolytic Processing of Hemofiltrate CC Chemokine 1 Generates a Potent CC Chemokine Receptor (CCR)1 and CCR5 Agonist with Anti-HIV Properties. JEM 192: 1501-1508 [Abstract] [Full Text]  
  • Rusconi, S., La Seta Catamancio, S., Citterio, P., Bulgheroni, E., Croce, F., Herrmann, S. H., Offord, R. E., Galli, M., Hirsch, M. S. (2000). Combination of CCR5 and CXCR4 Inhibitors in Therapy of Human Immunodeficiency Virus Type 1 Infection: In Vitro Studies of Mixed Virus Infections. J. Virol. 74: 9328-9332 [Abstract] [Full Text]  
  • Miller, R. J., Cairns, J. S., Bridges, S., Sarver, N. (2000). Human Immunodeficiency Virus and AIDS: Insights from Animal Lentiviruses. J. Virol. 74: 7187-7195 [Full Text]  
  • D'Souza, M. P., Cairns, J. S., Plaeger, S. F. (2000). Current Evidence and Future Directions for Targeting HIV Entry: Therapeutic and Prophylactic Strategies. JAMA 284: 215-222 [Abstract] [Full Text]  
  • Lee, S., Lapham, C. K., Chen, H., King, L., Manischewitz, J., Romantseva, T., Mostowski, H., Stantchev, T. S., Broder, C. C., Golding, H. (2000). Coreceptor Competition for Association with CD4 May Change the Susceptibility of Human Cells to Infection with T-Tropic and Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1. J. Virol. 74: 5016-5023 [Abstract] [Full Text]  
  • Torre, V. S., Marozsan, A. J., Albright, J. L., Collins, K. R., Hartley, O., Offord, R. E., Quiñones-Mateu, M. E., Arts, E. J. (2000). Variable Sensitivity of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates to Inhibition by RANTES Analogs. J. Virol. 74: 4868-4876 [Abstract] [Full Text]  
  • Steinberger, P., Andris-Widhopf, J., Buhler, B., Torbett, B. E., Barbas, C. F. III (2000). Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc. Natl. Acad. Sci. USA 97: 805-810 [Abstract] [Full Text]  
  • Schramm, B., Penn, M. L., Speck, R. F., Chan, S. Y., De Clercq, E., Schols, D., Connor, R. I., Goldsmith, M. A. (2000). Viral Entry through CXCR4 Is a Pathogenic Factor and Therapeutic Target in Human Immunodeficiency Virus Type 1 Disease. J. Virol. 74: 184-192 [Abstract] [Full Text]  
  • Maeda, K., Yoshimura, K., Shibayama, S., Habashita, H., Tada, H., Sagawa, K., Miyakawa, T., Aoki, M., Fukushima, D., Mitsuya, H. (2001). Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5. J. Biol. Chem. 276: 35194-35200 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»